Floatz logo

Pegteograstim

Pediatric Solid Tumor

Samsung Medical Centerprotein_peptidePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

20 Active assets in the Pediatric Solid Tumor cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Robbie Majzner
Phase 1/2CCC
Carboplatin
The Korean Society of Pediatric Hematology Oncology
Phase 2CCC
(+)-VINCRISTINE
St. Jude Children's Research Hospital
Phase 1/2CCC
Irinotecan
St. Jude Children's Research Hospital
Phase 1/2CCC
RH-ARG1-PEG-5,000 MW
University of Birmingham
Phase 1/2CCC

View all 26 →

Same molecule, other indications

Pegteograstim is also rated in:

neutropeniaDormant
CCC
Indicative ·
53 / 100
View asset →
malignant pancreatic neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
mantle cell lymphomaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →